Discover investment opportunities in Undervalued Pharma Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Undervalued Pharma Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Undervalued Pharma Stocks using our Smart AI Filter.
9 stocks found for "Undervalued Pharma Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.60 | ±27.2% | 15.6 | 3.47% | |||
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.74 | ±35.0% | 3.5 | 5.20% | |||
0.55 | ±27.3% | 5.1 | 0.00% | |||
0.35 | ±28.9% | 6.7 | 5.29% | |||
0.45 | ±25.0% | 14.4 | 3.19% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
0.34 | ±25.2% | 8.0 | 0.00% | |||
0.33 | ±27.9% | 8.6 | 4.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What factors could make Bristol-Myers Squibb (BMY) appear undervalued compared to its peers?
A: Bristol-Myers Squibb may be perceived as undervalued due to potential misalignment between its market price and intrinsic value, possibly influenced by recent patent expirations or litigation risks. Despite these concerns, some investors consider its diverse pharmaceutical pipeline and strong cash flow as a positive signal of its long-term value potential.
Q: How might Pfizer's (PFE) recent performance impact its valuation status?
A: Pfizer's valuation could be impacted by its recent performance related to the COVID-19 pandemic vaccine sales, which may have temporarily increased revenues. As demand normalizes, investors evaluate its core pharmaceutical products and development pipeline to assess if current valuations reflect future growth prospects.
Q: Why might Gilead Sciences (GILD) be attractive to value investors?
A: Gilead Sciences could attract value investors due to its strong revenue generation from antiviral treatments and a solid product pipeline, suggesting long-term profitability. However, shifting market trends and competitive pressures in the biotech space warrant a thorough risk assessment.
Q: In what ways does Merck's (MRK) financial health contribute to its market valuation?
A: Merck's market valuation benefits from its robust financial health, marked by consistent earnings and strong R&D investments. Its leading positions in oncology and vaccines signal potential competitive advantages, though global regulatory developments may pose risks.
Q: What role does innovation play in AstraZeneca's (AZN) perceived market value?
A: AstraZeneca's perceived market value is bolstered by its pipeline of innovative drugs, particularly in oncology and respiratory fields. Successful clinical trials and regulatory approvals could underpin its valuation, though geopolitical factors might impact operational stability.
Q: How does Eli Lilly's (LLY) portfolio affect its valuation as an investment?
A: Eli Lilly's valuation is supported by its diversified product portfolio, including strong positions in diabetes and oncology. Its growth prospects rely on successful new drug releases but must be weighed against pricing pressures and patent expirations.
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read morePresident Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Read more